Day: April 24, 2025

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s...

ORLANDO, FL, April 24, 2025 (GLOBE NEWSWIRE) — Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA), a global market leader in 4D/5D/6D imaging sonar technology and new generation diving technology (DAVD) for real time subsea intelligence, today reported that its UK, Portland based Defense Engineering Services Business, Coda Octopus Martech Limited, recently received an order from one of its established long term customers, a leading and longstanding UK Defense Contractor, for sub-components which will form part of a suite of autonomous mine sweeping systems. Annmarie Gayle, CODA’s Chairman and CEO, commented: “We are very pleased to see contracts relating to European Defense Programs being fast tracked and contracting barriers being removed to expedite Defense Programs. Since 1988, Martech has been a well-established...

PRINCETON JUNCTION, N.J., April 24, 2025 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (NYSE: MG), the leading global provider of integrated, technology-enabled asset protection solutions, today announced the launch of MISTRAS Data Solutions, a unified brand that consolidates the company’s data-centric services, software solutions, and technology under one umbrella. MISTRAS Data Solutions brings together a powerful suite of capabilities and brands, including: PCMS®, New Century Software, Integrity Plus, Onstream, MISTRAS OneSuite®, Sensoria®, CALIPERAY®, VPAC®II, and Triple 5. This strategic unification accelerates MISTRAS’ evolution into the first data-driven asset integrity provider, integrating advanced analytics, industrial IoT, and inspection data software and management systems to support the full lifecycle of asset protection—from...

COOTAMUNDRA, Australia, April 24, 2025 (GLOBE NEWSWIRE) — Australian Oilseeds Holdings Limited, a manufacturer and seller of sustainable edible oils to customers globally, today issued a letter to shareholders from Gary Seaton, Chairman and Chief Executive Officer, that highlights recent performance and future milestones. Dear Fellow Shareholders, Across the globe, 2024 presented serious challenges including the ongoing war in Ukraine and serious conflicts in the Middle East and growing geopolitical discord, notably with China. Our hearts go out to those whose lives are profoundly affected by these events. Despite the unsettling geopolitical discord, we are pleased with our progress since launching the Company, as a Nasdaq listed company, and its unique products of Non-GMO cold-pressed and chemically-free processed oils. Within...

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event. About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical...

IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on the company’s Investor Relations website, https://ir.cgoncology.com. An archive will be available following the completion of the call. About...

TORONTO, April 24, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company’s website. About Cronos Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property...

CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extension trial for brilaroxazine in schizophrenia at the 2025 American Society of Clinical Psychopharmacology (ASCP) annual meeting, taking place May 27-30, 2025, in Scottsdale, AZ. Details for the poster presentation can be found below: Title: Brilaroxazine’s Effects on Efficacy, Safety, Adherence, and Biomarkers in the Phase 3 Recover 12-Month...

More than a dozen AON leaders to speak on panels focused on advocacy, innovation and access in independent community oncology FORT MYERS, Fla., April 24, 2025 (GLOBE NEWSWIRE) — American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, today announced that it will participate in 14 speaking sessions at the 2025 Community Oncology Alliance (COA) Annual Conference. The event, themed Empower & Advocate: Independent Community Oncology, will take place April 29-30 in Orlando, Florida.“At AON, we’re committed to supporting local practices because they bring immense value to patients and communities,” said Stephen “Fred” Divers, MD, AON’s chief medical officer, medical oncologist at Genesis Cancer and Blood Institute, and conference co-chair. “The conference theme of empowerment and advocacy...

~ Strong start to the year with 1Q25 financial results ~~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 28, 2025.   First Quarter 2025 Highlights (compared to First Quarter 2024, except as noted)Sales increased 7% to $437 million, with organic growth of 6%. GAAP operating income increased $11 million to $50 million, an increase of 28%. Non-GAAP adjusted operating income increased $9 million to $71 million, an increase of 14%. GAAP income (loss) from continuing operations decreased $43 million to a $22 million loss, primarily from debt conversion inducement expense related to the exchange of 2028 convertible notes. Non-GAAP adjusted net...